Atara Biotherapeutics has renegotiated a $9.0 million milestone payment to HealthCare Royalty (HCRx), extending the due date from June 2026 to January 2028. This move is intended to provide the company with greater financial flexibility as it addresses FDA concerns regarding tabelecleucel (tab-cel) following a recent Complete Response Letter (CRL).

Atara Biotherapeutics reported a significant increase in total revenues to $98.1 million for Q1 2025, up from $27.4 million in Q1 2024, primarily due to revenue recognized from the completion of performance obligations under its Pierre Fabre agreement. The company also reported a net income of $38.0 million, a substantial improvement from a net loss in the prior year period. Operating expenses decreased slightly year-over-year, and the company secured additional financing to extend its cash runway into Q1 2026.

Atara Biotherapeutics reported a net loss of $12.7 million for Q4 2024, a significant improvement from the $60.5 million loss in Q4 2023. Total revenue for the quarter was $32.753 million, primarily driven by commercialization revenue. The company is focusing on EBVALLO and has paused its CAR-T programs.

Atara Biotherapeutics reported Q3 2024 financial results, including total revenues of $40.2 million and a net loss of $21.9 million, with cash, cash equivalents, and short-term investments totaling $67.2 million as of September 30, 2024. The company's cash runway is expected to extend into 2027, supported by anticipated milestones, inventory purchases, and operating efficiencies.

Atara Biotherapeutics reported increased revenue for Q2 2024, driven by the expanded partnership with Pierre Fabre and accelerated recognition of deferred revenue. The company is advancing its pipeline, including tab-cel and ATA3219, with key milestones expected in the coming year. A leadership transition was announced, with Pascal Touchon becoming Chairman and Cokey Nguyen assuming the role of President and CEO.

Atara Biotherapeutics reported a net loss of $31.8 million, or $0.23 per share, for the first quarter 2024, compared to a net loss of $74.8 million, or $0.72 per share, for the same period in 2023. Total revenues were $27.4 million for the first quarter 2024, as compared to $1.2 million for the same period in 2023. The company's cash, cash equivalents, and short-term investments totaled $46.2 million as of March 31, 2024.

Atara Biotherapeutics reported a net loss of $60.5 million for Q4 2023. The company is progressing with its BLA submission for Tab-cel and expanding its allogeneic CAR T pipeline.

Atara Biotherapeutics announced an expanded global partnership with Pierre Fabre Laboratories for tab-cel, receiving up to $640 million and significant double-digit tiered royalties. The company is restructuring to reduce workforce by 30% and focus on ATA188 and AlloCAR-T programs. Atara's cash runway is extended into Q3 2025. The net loss for the third quarter 2023 was $69.8 million.

Atara Biotherapeutics reported a net loss of $71.1 million for the second quarter of 2023. They announced IND clearance for ATA3219. Discussions with the FDA and potential commercial partners for tab-cel in the U.S. are progressing well.

Atara Biotherapeutics reported a net loss of $74.8 million for Q1 2023, with cash, cash equivalents, and short-term investments totaling $205.4 million. The company believes its current cash resources will fund planned operations into Q2 2024. Discussions with the FDA regarding tab-cel are progressing, and the first patients in Europe have been treated with EBVALLO following the transfer of EC Marketing Authorization to Pierre Fabre.

Atara Biotherapeutics announced a positive CHMP opinion for Ebvallo and continues to advance its pipeline, including ATA188 for progressive MS. The company's cash, cash equivalents, and short-term investments totaled $265.4 million as of September 30, 2022. Net loss for the quarter was $84.1 million, or $0.82 per share.

Atara Biotherapeutics reported a net income of $18.5 million, or $0.18 per share, for the second quarter 2022, compared to a net loss of $83.8 million, or $0.91 per share, for the same period in 2021. The company's cash, cash equivalents, and short-term investments totaled $331.3 million as of June 30, 2022. Atara plans to focus on R&D activities, prioritizing key pipeline assets and reducing cash burn.

Atara Biotherapeutics reported a net loss of $88.1 million, or $0.87 per share, for the first quarter of 2022. As of March 31, 2022, cash, cash equivalents, and short-term investments totaled $301.8 million, excluding the $100 million upfront payment from FUJIFILM Diosynth Biotechnologies (FDB) received in April.

Atara Biotherapeutics reported a net loss of $93.3 million for Q4 2021, with cash, cash equivalents, and short-term investments totaling $371.1 million as of December 31, 2021. The company is progressing its pipeline, including tab-cel and ATA188, but faces regulatory challenges with the FDA regarding tab-cel's BLA submission in the U.S.

Atara Biotherapeutics reported financial results for the third quarter of 2021, highlighting positive data from the Phase 3 ALLELE study for Tab-cel and progress with ATA188 for multiple sclerosis. The company is preparing for regulatory submissions and continues to advance its CAR T programs.

Atara Biotherapeutics reported a net loss of $83.8 million, or $0.91 per share, for the second quarter of 2021. The company's cash, cash equivalents, and short-term investments totaled $373.4 million as of June 30, 2021. License and collaboration revenue was $3.9 million for the second quarter 2021.

Atara Biotherapeutics reported a net loss of $78.3 million, or $0.86 per share, for the first quarter of 2021. The company's cash, cash equivalents, and short-term investments totaled $435.2 million as of March 31, 2021. License and collaboration revenue was $3.6 million for the quarter, stemming from the Bayer Collaboration Agreements.

Atara Biotherapeutics reported a net loss of $81.3 million for Q4 2020. The company is on track to complete tab-cel® BLA submission in Q3 2021 and ATA188 Phase 2 RCT enrollment, enabling an interim analysis in H1 2022.

Atara Biotherapeutics reported a net loss of $74.3 million for the third quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $327.2 million as of September 30, 2020, which is expected to fund operations into 2022. The company is preparing for tab-cel® submissions, and then approval and launch.

Atara Biotherapeutics reported a net loss of $77.5 million, or $1.14 per share, for the second quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $347.7 million as of June 30, 2020, which is expected to fund planned operations into 2022. The company is on track to initiate a BLA submission for tab-cel® for patients with EBV+ PTLD by the end of 2020.

Atara Biotherapeutics reported a net loss of $73.5 million, or $1.20 per share, for the first quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $214.6 million as of March 31, 2020, which is expected to fund operations into the second quarter of 2021.

Atara Biotherapeutics reported a net loss of $78.5 million for the fourth quarter of 2019. The company's cash, cash equivalents, and short-term investments totaled $259.1 million as of December 31, 2019, which, combined with proceeds from the ATM facility, are expected to fund operations into the second quarter of 2021.